Description
Arbidol Maximum Pharmacodynamics
Antiviral agent. Specifically suppresses in vitro influenza viruses A and B (Influ-enzavirus A, B), including highly pathogenic subtypes A(H1N1)pdm09 and A(H5N1), as well as other viruses – causative agents of acute respiratory viral infections (ARI) (Coronavirus (Coronavirus) associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus). By the mechanism of antiviral action it belongs to fusion inhibitors (fusion), it interacts with hemagglutinin of the virus and prevents fusion of lipid coating of the virus and cell membranes. It has a moderate immunomodulatory effect and increases resistance of the organism to viral infections. It has interferon-inducing activity: in tests on mice interferon induction was observed in 16 hours, and high titers of interferon were kept in blood up to 48 hours after injection. It stimulates cellular and humoral immune reactions: it increases the number of lymphocytes in blood, in particular the number of T-cells (CD3), increases the number of T-helpers (CD4) without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates the phagocytic function of macrophages and increases the number of natural killer (NK-cells).
Therapeutic effectiveness in viral infections is manifested in reduction of duration and severity of the course of disease and its main symptoms, as well as in reduction of the frequency of development of complications due to viral infection and exacerbations of chronic bacterial diseases.
In treatment of flu or acute respiratory viral infections in adults, clinical trial showed that Arbidol® effect in adults is most expressed in acute period of disease and is expressed by reduction of terms of resolution of disease symptoms, decrease of disease severity and shortening of terms of virus elimination.
Therapy with Arbidol® results in higher rate of resolution of disease symptoms on the third day of therapy compared to placebo. In 60 hours after the therapy start, the resolution of all symptoms of laboratory confirmed influenza is more than 5 times higher than in the placebo group.
A significant effect of Arbidol® was found on the rate of elimination of influenza virus, which, in particular, was manifested by a decrease in the frequency of detection of RNA virus on the 4th day.
The drug is considered to be low-toxic (LD50 > 4 g/kg). It does not have any negative effect on the human body when administered orally in the recommended doses.
Indications
Prevention and treatment in adults and children: influenza A and B, other acute respiratory infections.
Complex therapy of recurrent herpetic infection.
Prevention of postoperative infectious complications.
Complex treatment of acute intestinal infections of rotavirus etiology in children over 6 years.
Contraindications .
Hypersensitivity to umifenovir or any component of the drug, children under 12 years of age. The first trimester of pregnancy. Breast-feeding period.
Dosage and administration
- Inside, before a meal.
Single dose for adults and children over 12 years – 200 mg (1 capsule).
Indication Treatment regimen
The preparation - Adults and children over 12 years of age:
Non-specific prophylaxis during epidemics of influenza and other acute respiratory viral infections in a single dose
Twice a week for 3 weeks. - Non-specific prophylaxis at direct contact with influenza and other acute respiratory viral infections at a single dose
Once a day for 10-14 days. - Treatment of influenza and other acute respiratory viral infections at a single dose
4 times a day
(every 6 hours) during 5 days.
Complex therapy of recurrent herpetic infection in a single dose
4 times a day
(every 6 hours) during 5-7 days and then in a single dose twice a week during 4 weeks.
Prophylaxis of postoperative infectious complications in a single dose
2 days before the operation and then on the 2nd and 5th day after the operation. - In children from 12 years old:
Complex therapy of acute intestinal infections of ro-tavirus etiol-gy
In a single dose
4 times a day
(every 6 hours) for 5 days.
The drug administration starts from the moment of the first symptoms of influenza and other ARVI, preferably not later than 3 days from the beginning of the disease.
If after using Arbidol® Maximum during three days in treatment of influenza and other acute respiratory viral infections the disease symptoms, including high temperature (38 °c and more) remain severe, it is necessary to consult a physician in order to determine the reasonableness of using the drug. - Use the drug only according to the indications, the method of administration and in the doses specified in the instructions.
- During the treatment of influenza and acute respiratory infections, concomitant symptomatic therapy is possible, including antipyretic drugs, mucolytic and local vasoconstrictors.
